Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Expands By 555.2%

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 62,900 shares, a growth of 555.2% from the May 15th total of 9,600 shares. Approximately 0.0% of the company's stock are short sold. Based on an average trading volume of 222,800 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Stock Down 1.6%

Shares of OTCMKTS ALPMY traded down $0.16 during midday trading on Friday, hitting $9.63. 81,803 shares of the company's stock were exchanged, compared to its average volume of 198,135. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80. Astellas Pharma has a twelve month low of $8.37 and a twelve month high of $13.14. The company has a market cap of $17.43 billion, a PE ratio of -43.77 and a beta of 0.23. The firm's fifty day simple moving average is $9.58 and its 200-day simple moving average is $9.70.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.12. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Research analysts predict that Astellas Pharma will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.